Modified albumin-bilirubin predicted survival of unresectable hepatocellular carcinoma patients treated with immunotherapy

Table 2 Efficacy outcomes of atezolizumab plus bevacizumab¹, n (%)

Variables	Total, n = 61	mALBI 1 + 2a, n = 39	mALBI 2b + 3, n = 22	P value
Complete response	4 (6.6)	3 (7.7)	1 (4.5)	1.000
Partial response	13 (21.3)	11 (28.2)	2 (9.1)	0.110
Stable disease	21 (34.4)	12 (30.8)	9 (40.9)	0.420
Objective response rate	17 (27.9)	14 (35.9)	3 (13.6)	0.060
Disease control rate	38 (62.3)	26 (66.7)	12 (54.5)	0.350
Progressive disease	23 (37.7)	13 (33.3)	10 (45.5)	0.350

¹The number of patients who had available data on treatment response evaluation were 61/83 patients (73.5%), and 22/83 patients (26.5%) had died prior to treatment response evaluation. mALBI: Modified albumin-bilirubin.